Service Definition Document

Service Description

PharmChek® by SCRAM Systems is the sole manufacturer of the PharmChek drug monitoring technology that facilitates non-invasive transdermal drug monitoring 24 hours a day. Otherwise known as the *"Sweat Patch" or "Drug Patch,"* PharmChek is the only FDA-cleared transdermal sweat patch on the market.

PharmChek has been implemented for more than 35 years in the United States, and the results have been forensically defended in more than 80 court hearings, including those evaluated under the Frye and Daubert standards of judicial admissibility. PharmChek was further affirmed as a valid and reliable drug testing device by the 8th Circuit Court of Appeals *(U.S. v. Meyer, 2007).*

The PharmChek patch consists of a cellulose collection pad secured within a transparent, surgical-grade polyurethane film that adheres to the donor's skin for approximately 7–10 days.



Longevity and Additional Security. An optional overlay, made of the same polyurethane film, can also be applied that may extend the wear time for some donors to 14 days.

The patches and overlays have a two-year shelf life from the date of purchase. Each patch is manufactured with a unique patch ID# that is recorded on Part 1 of the Chain of Custody Form (CCF) at application and removal.

How PharmChek Works. Whilst wearing the PharmChek drug patch, the cellulose pad continuously collects the non-volatile components of sweat, including ingested drugs of abuse. The adhesive film functions as a semi-permeable, non-occlusive membrane that allows oxygen, water vapor, and gases to pass through while preventing contaminants from the environment from penetrating.

Drug Detection and Confirmation. PharmChek can detect and confirm donor use of the following drugs:

Analyte Group	Analyte	Cut-Off
AMPHETAMINES	Amphetamine	25 ng/Patch
	Methamphetamine	25 ng/Patch
	MDMA	25 ng/Patch
COCAINE	Cocaine	25 ng/Patch
	Benzoylecgonine	25 ng/Patch
BENZODIAZEPINES	Diazepam	3 ng/Patch
	Nordiazepam	3 ng/Patch
	Oxazepam	3 ng/Patch
	Temazepam	3 ng/Patch
	Lorazepam	3 ng/Patch
	Alprazolam	3 ng/Patch
OPIATES	Morphine	25 ng/Patch
	Codeine	25 ng/Patch
	Dihydrocodeine	25 ng/Patch
	6-MAM	25 ng/Patch
	Thebaine	25 ng/Patch
OPIOIDS	Oxycodone	25 ng/Patch
	Tramadol	25 ng/Patch
	Methadone	25 ng/Patch
	EDDP	25 ng/Patch
	Buprenorphine	1 ng/Patch
	Norbuprenorphine	1 ng/Patch
CANNABIS	(Δ-9)-THC	2 ng/Patch
KETAMINE	Ketamine	25 ng/Patch

Anti-Circumvention. PharmChek's tamper-evident features help the trained observer to detect attempts at removal and the re-application of the patch. Due to the tamper-evident technology, once removed, it cannot be reapplied with the integrity of the initial application.

Authorised Removal and the Chain of Custody. At the end of the wear period the trained observer completes Part 2 of the Chain of Custody Form (CCF) and removes the pad from the film. The pad is collected using single use tweezers and secured in the specimen bag. The specimen bag is sealed with a tamper-evident seal and endorsed by both the donor and observer. A matching barcode sticker from the CCF is affixed to the specimen bag and transport bag to ensure proper identification and tracking, then shipped to the laboratory for analysis.

Data Protection and Transfer of CCF and Results. There are two operating models that can be implemented. The first will utilise the wearer's personal details, which will be held on the customer's database and only transferred to the laboratory via the CCF.

The second operating model will allow for pseudonymised data to be entered into the CCF and only the patch ID# and a reference number will be provided to the laboratory. The patch ID# is only used at the agency-level to ensure the same patch that was applied is the same as was removed and is off-set as another tamper-evident feature. The lab does not record it on the report.

Analysis & Reporting. When the specimen is received at the lab it is analyzed by liquid chromatography–tandem mass spectrometry (LC-MS/MS) in accordance with forensic testing best standards, ensuring that all results are confirmatory. Hence, it can be trusted and relied upon to be presented before a court of law. Chain of custody is maintained at the laboratory throughout testing to preserve specimen integrity and to provide complete documentation from specimen collection through to the final report to the supervising authority.

The Laboratory. We partner with UK based laboratories that are UKAS and ISO 17025 accredited to analyze all PharmChek specimens.

Onboarding Support

SCRAM Systems will develop a simplified and customised onboarding process for each agency that contracts them as their service provider. This process will include, but is not limited to:

- Customer setup
- Live training sessions
- Customer demonstrations
- Deployment planning and execution

Our Field Support Services team provides professional service and support for SCRAM Systems customers by performing onsite initial and refresher training. They bridge the gap between programme adoption and customer support by providing more than 1,500 hours of training to SCRAM Systems partners and agencies each year. In addition, a UK-based team is available to help create and/or maintain a monitoring program tailored specifically to your budget, policies, procedures, and goals.

Contact information

Amit Sethi | Director of European Operations
Address: Alcohol Monitoring Systems Ltd, Signature by Regus, 2nd Floor Berkeley Square House, Berkeley Street, W1J 6BD
Email: asethi@scramsystems.com
https://www.scramsystems.com/scram-international/gb/

PHARMCHEK®
by SCRAM Systems

Driving Accountability & Behavioral Change Worldwide



The Solution at a Glance

The PharmChek® Sweat Patch is an FDA-cleared, tamper-evident medical device that monitors drug use continuously for an average of 10 days. Unlike urine or oral fluid tests, which provide only a single point-in-time result, PharmChek captures a full week or more of evidence.

The PharmChek® Sweat Patch is a reliable, non-invasive, and cost-effective approach to long-term drug monitoring in justice and rehabilitation settings.

Global Use and Adoption

With more than 35 years of real-world use, over 50 independent peer-reviewed studies, and repeated courtroom validation, PharmChek® is trusted by judges, probation agencies, and treatment courts worldwide.

PharmChek® is used extensively in the United States and is gaining adoption internationally in criminal justice, family law, and within treatment programs.


Courts and agencies value its ability to:

- Provide continuous accountability
- Detect drug use that other methods miss
- Detect attempts to tamper, manipulate, or circumvent monitoring
- Offer humane, trauma-informed collection

These qualities make PharmChek® a trusted solution for a reliable and defensible drug monitoring solution.

A SUCCESS STORY:

The Federal Probation Districts of Guam and Northern Mariana Islands



Behind the Data

Although the districts had used PharmChek® intermittently prior to 2022, a renewed **commitment to training** and **structured implementation** marked a turning point. As the program expanded, compliance improved—not simply because more patches were applied, but because probationers adjusted their behavior under consistent, well-supported monitoring. This data reflects more than growth; it shows the outcome of a fully integrated program with intentional design, training, and stakeholder engagement.

Technical Function

Collection Method:
Worn on the skin, the patch captures insensible perspiration, storing drug evidence in a sealed absorbent pad.

Detection Window:
Detects use 24–48 hours prior to application, and continuously throughout the wear period.

Scientific Rigor:
All presumptive positives are automatically confirmed by LC-MS/MS, the platinum standard in forensic toxicology.

FDA Clearance:
PharmChek® is the only sweat patch with FDA clearance, giving courts and agencies confidence in its safety, reliability, and admissibility.

Financial Viability

PharmChek® improves accountability while reducing long-term costs.

Fewer Collections:
One patch replaces 2–3 urine tests per week.

Lower Lab Burden:
Confirmation testing is included; no hidden retesting costs.

Staff Efficiency:
Eliminates the need for observed urine collection, reducing staff hours and logistical strain.

Proven Funding Models:
Programs sustain PharmChek® through existing budgets, grants, or by redirecting year-end revert-back funds.

Transparent Pricing:
Agencies pay only for services rendered, with no bundled overcharges.



Why PharmChek® Matters

- Continuous, tamper-evident monitoring
- Scientifically rigorous and court-admissible worldwide
- Humane, trauma-informed collection
- Lower cost and higher efficiency than traditional methods
- Backed by decades of research and adoption

PharmChek® delivers accountability, equity, and defensibility for justice systems worldwide.

Its unique combination of scientific rigor and practical efficiency makes it a trusted tool not only for detecting drug use but also for supporting rehabilitation and reducing recidivism. By closing the gaps left by traditional testing methods, PharmChek® strengthens public confidence in monitoring programs and delivers fair, defensible outcomes for courts and communities.

Analyte	Cut-Off (ng/Patch)
Amphetamines	
Amphetamine	25
Methamphetamine	25
MDMA	25
Cocaine	
Cocaine	25
Benzoylecgonine	25
Benzodiazepines	
Diazepam	3
Nordiazepam	3
Oxazepam	3
Temazepam	3
Lorazepam	3
Alprazolam	3
Opiates	
Morphine	25
Codeine	25
Dihydrocodeine	25
6-MAM	25
Thebaine*	25
Opioids	
Oxycodone	25
Tramadol	25
Methadone	25
EDDP	25
Buprenorphine	1
Norbuprenorphine*	1
Cannabis	
(Delta-9) - THC	2
Ketamine	
Ketamine	25

*thebaine assessed at Limit of Identification for interpretive purposes only

PHARMCHEK
by SCRAM Systems

Collateral